Electronic drug delivery systems ensure precise and controlled administration of medications. These innovative systems enhance treatment efficacy, improve patient adherence, and offer personalized dosage regimens. With features such as automated delivery and real-time monitoring, they provide healthcare professionals with valuable insights, promoting better disease management. It contributes to improved patient outcomes, making drug administration more accurate, convenient, and tailored to individual needs.
Access full Report @ https://www.databridgemarketresearch.com/reports/global-electronic-drug-delivery-systems-market
Data Bridge Market Research analyses the Global Electronic Drug Delivery Systems Market which was USD 16,139.89 million in 2022, is expected to reach up to USD 17,576.34 million by 2030, and is expected to undergo a CAGR of 8.9% during the forecast period 2023-2030. The rapid progress in microtechnology serves as a key driver for the market. This advancement empowers the creation of highly sophisticated devices capable of precise dosage control, usage monitoring, and seamless connectivity with healthcare providers via mobile apps and cloud platforms.
Key Findings of the Study
Rising chronic diseases are expected to drive the market's growth rate
The electronic drug delivery systems market is driven by the growing burden of chronic diseases such as diabetes, cardiovascular disorders, and respiratory conditions. This surge in prevalence creates a demand for advanced drug delivery systems that can offer continuous monitoring and precise medication delivery. Electronic devices, such as smart pumps and wearable technologies, enable real-time monitoring of patient's health metrics and facilitate targeted drug administration. The market is propelled by the need for innovative solutions that address the complexities of chronic diseases, offering patients more effective and personalized therapeutic interventions.
Report Scope and Market Segmentation
Report Metric
|
Details
|
Forecast Period
|
2023 to 2030
|
Base Year
|
2022
|
Historic Years
|
2021 (Customizable to 2015-2020)
|
Quantitative Units
|
Revenue in USD Million, Volumes in Units, Pricing in USD
|
Segments Covered
|
Type (Electronic Infusion Pumps, Electronic Injection Pens, Electronic Auto-Injectors, Electronic Inhalers, Electronic Capsules, Others), Component (Sensors, Wireless Communicator and Antennas, Micro Pumps and Flow Regulators, Drug Reservoir, Microcontroller, Others), Connectivity (Bluetooth Low Energy (BLE), Wi-Fi, Ethernet, NB-IoT, Others), System Type (Battery-Powered Systems, Rechargeable Systems), Application (Diabetes, Asthma and Chronic Obstructive Pulmonary Disease (COPD), Multiple Sclerosis, Growth Hormone Therapy, Immunodeficiency Disease, Cardiovascular Disease, Thalassemia, Others), End User (Home Healthcare, Hospitals, Clinics, Ambulatory Centers, Others)
|
Countries Covered
|
U.S., Canada, Mexico, Germany, Italy, U.K., France, Spain, Netherland, Belgium, Switzerland, Turkey, Russia, Rest of Europe, Japan, China, India, South Korea, Australia, Singapore, Malaysia, Thailand, Indonesia, Philippines, Rest of Asia- Pacific, Brazil, Argentina, Rest of South America, South Africa, Saudi Arabia, UAE, Egypt, Israel, Rest of Middle East and Africa
|
Market Players Covered
|
AstraZeneca (U.K.), Amgen Inc. (U.S.), Ypsomed AG (Switzerland), Merck KGaA (U.S.), Bayer AG (Germany), Nemera (France), F. Hoffmann-La Roche Ltd (Switzerland), Teva Pharmaceuticals USA, Inc. (U.S.), AptarGroup, Inc. (U.S.), Novo Nordisk A/S. (Denmark), ViCentra B.V. (Netherlands), Medtronic (U.S.), United Therapeutics Corporation (U.S.), Companion Medical (U.S.), Tandem Diabetes Care, Inc. (U.S.), Debiotech S.A. (Switzerland), Canè S.p.A (Italy), Insulet Corporation (U.S.), BD (U.S.), and B. Braun Melsungen AG (Germany)
|
Data Points Covered in the Report
|
In addition to the insights on market scenarios such as market value, growth rate, segmentation, geographical coverage, and major players, the market reports curated by the Data Bridge Market Research also include depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework
|
Segment Analysis:
The global electronic drug delivery systems market is segmented on the basis of type, component, connectivity, system type, application, and end-user.
- On the basis of type, the global electronic drug delivery systems market is segmented into electronic infusion pumps, electronic injection pens, electronic auto-injectors, electronic inhalers, electronic capsules, and others
- On the basis of component, the global electronic drug delivery systems market is segmented into sensors, wireless communicator and antennas, micro pumps and flow regulators, drug reservoir, microcontroller, and others
- On the basis of connectivity, the global electronic drug delivery systems market is segmented into bluetooth low energy (ble), Wi-Fi, ethernet, Nb-IoT, and others
- On the basis of system type, the global electronic drug delivery systems market is segmented into battery-powered systems, and rechargeable systems
- 根據應用，全球電子藥物輸送系統市場細分為糖尿病、氣喘和慢性阻塞性肺病 (COPD)、多發性硬化症、生長激素治療、免疫缺陷病、心血管疾病、地中海貧血等
- 根據最終用戶，全球電子藥物傳輸系統市場分為家庭醫療保健、醫院、診所、門診中心和其他
主要參與者
Data Bridge Market Research 認為以下公司是全球電子藥物輸送系統市場的主要參與者，在全球電子藥物輸送系統市場中，阿斯特捷利康 (英國)、安進公司 (美國)、Ypsomed AG (瑞士)、默克公司 (美國)、拜耳公司 (德國)、Nemera (法國)、F. Hoffmann-La Roche Ltd (瑞士)、Tevace Ltd.
市場發展
- 2022 年，Gufic Biosciences Ltd 以實惠的價格推出了突破性的藥物輸送系統雙室袋，在印度產生了重大影響。此舉標誌著該國朝著提高先進醫療技術可近性邁出了重要一步
- 2022 年，武田取得了一個里程碑，獲得美國 FDA 批准單劑量預充式註射器 (PFS) 中的 TAKHZYRO (lanadelumab-flyo) 注射。這項批准凸顯了該藥物在預防遺傳性血管性水腫 (HAE) 發作方面的有效性，並為 12 歲及以上的成人和兒童患者提供了一種方便且用戶友好的解決方案
- 2021年，默克與貝朗達成策略合作，專注於開發用於藥物傳遞的生物電子設備。此次合作彰顯了雙方致力於推動藥物管理創新解決方案的承諾，可望徹底改變藥物的輸送和管理方式
- 2020 年，美敦力公司推出了 Efficio，這是一款基於雲端的資料管理軟體，專為與 SynchroMed II 鞘內給藥系統配合使用而設計。這項發展旨在提高臨床醫生管理標靶藥物輸送幫浦實務的效率，特別是針對患有慢性疼痛、癌症疼痛和嚴重痙攣的患者。
區域分析
從地理上看，全球電子藥物輸送系統市場報告涵蓋的國家有美國、加拿大、墨西哥、德國、義大利、英國、法國、西班牙、荷蘭、比利時、瑞士、土耳其、俄羅斯、歐洲其他地區、日本、中國、印度、韓國、澳洲、新加坡、馬來西亞、泰國、印尼、菲律賓、亞太其他地區、巴西、阿根廷、其他地區、南非、沙烏地阿拉伯、阿聯酋、其他地區
根據 Data Bridge 市場研究分析：
2023-2030 年預測期內，北美是全球電子藥物輸送系統 市場的主導地區
由於電子輸液幫浦在北美的廣泛應用，北美在全球電子藥物傳輸系統市場佔據主導地位。電子輸液幫浦是一種精確輸送液體和藥物的設備，其使用量大幅增加。先進的醫療保健基礎設施、較高的慢性病盛行率以及採用創新醫療技術的傾向，使北美在該市場上佔據領先地位。
預計2023-2030 年預測期內，亞太地區將成為全球電子藥物傳輸系統 市場成長最快的地區
預計 2023 年至 2030 年期間亞太地區的市場成長率將最高。這主要歸因於該地區氣喘和心臟病發病率的上升，從而推動了對先進藥物輸送系統的需求。亞太地區製藥業的同步發展和成熟促進了這一增長，因為電子藥物輸送系統符合該行業對更有效、更方便患者的治療方案的追求。
有關全球電子藥物輸送系統市場報告的更多詳細信息，請點擊此處 - https://www.databridgemarketresearch.com/reports/global-electronic-drug-delivery-systems-market
